Call For More Information (410) Skype715-2111
Blog: Recent Posts
  1. ACOG Opinion on Noninvasive Prenatal Genetic Testing

    Noninvasive Prenatal Testing for Fetal Aneuploidy ABSTRACT: Noninvasive prenatal testing that uses cell free fetal DNA from the plasma of pregnant women offers tremendous potential as a screening tool for fetal aneuploidy. Cell free fetal DNA testing should be an informed patient choice after pretest counseling and should not be...
  2. Choosing to Participate in Prenatal Screening for Down Syndrome

    New prenatal screening test for Down syndrome raises questions LEISA SCOTT IT RAINED the day they got the news. Big, pelting drops, as if some screenwriter well-versed in melodrama was dictating the scene. Annie Love couldn’t take the call. She’d been going “slowly nuts” waiting for diagnosis day to arrive...

How’s it done?

Ravgen’s core technology is based on its ability to increase the percentage of fetal DNA that is found in the mother’s blood. Through its research with free floating fetal DNA, the company has developed and patented a variety of noninvasive prenatal tests that simply require a safe blood draw from the mother. Currently, the focus for Ravgen’s core technology is on testing for single gene disorders, such as cystic fibrosis, sickle cell anemia, and the Jewish panel, as well as prenatal paternity testing. To complete our Prenatal DNA Paternity test, we require a safe blood draw from the mother’s arm to match the baby’s DNA with a father’s DNA. We can conduct the paternity test after the 8th week of pregnancy with over 99% accuracy. Please contact Ravgen at (410) 715-2111 to make convenient arrangements.